Indeed, the enhanced signatures for c-Myc and BRD4, and the functional protection against two distinct BET inhibitors, driven by D463H over-expression in glioma cells, provides strong evidence that this mutant preferentially interacts with the BRD4 axis. This evidence concerns the gene MYC and glioma.